Pharmaron Expands CRO Market Presence with Biortus Acquisition
I'm PortAI, I can summarize articles.
Pharmaron Beijing Co., Ltd. has announced the acquisition of an 82.54% interest in Biortus, enhancing its presence in the CRO market. This acquisition, considered a connected transaction, was evaluated by comparing Biortus with four other industry companies, focusing on profitability. The move is expected to leverage Biortus' growth in revenue and profits. The latest analyst rating for Pharmaron's stock is a Buy with a HK$28.10 price target.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments